TABLE 1.
A summary of new systemic drug therapies for psoriasis
DRUG | CURRENT STATUS AND OBSERVATIONS | COMMENTS |
---|---|---|
Certolizumab-Pegol | Developed for treating Crohn’s disease | |
Ustekinumab | Antagonizes IL-23 by targeting the p19 subunit (not shared) | Pure IL-23 antagonist; adverse events include risk of serious infection |
Guselkumab | Phase 2 dose-ranging studies resulted in comparisons to adalimumab | |
Tidrakizumab | Phase 2 dose-ranging studied, good PASI-90 scores at 12 weeks. Antagonizes IL-23 by targeting p19 subunit | Well-tolerated |
Boehringer-Ingelheim 655066 | Novel monoclonal antibody, phase 2 proof-ofconcept study with 58% achieving PASI-90 and remaining clear at 66 weeks | Subcutaneous injection, may need dosing only every four months |
Secukinumab, ixekizumab, and brodalumab | IL-17 antagonists | Secukinumab approved in U.S. for psoriasis in May 2015 |